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AbstrACt
Objectives Regular physical exercise may preserve β cell 
function in newly diagnosed adults with type 1 diabetes 
(T1D). However, clinical trials to test this theory require the 
recruitment and retention of adults with new-onset T1D, 
which can be challenging. We sought to determine the 
overall experiences of newly diagnosed adults with T1D in 
an exercise study, to understand issues that influence the 
retention of trial participants in such studies.
Design Qualitative methodology using individual face-
to-face (n=6) and telephone interviews (n=14). Interview 
transcripts were thematically analysed using the 
framework method.
setting The study took place at five participating UK 
hospitals.
Participants Twenty participants, aged 19–55 years, in 
the Exercise for Type 1 Diabetes study were interviewed to 
explore their study experiences and identify motivators and 
deterrents towards the study. Participants in control and 
intervention arms were interviewed, as were people with 
T1D who had completed (n=16) and withdrawn (n=4).
results Participants revealed barriers and facilitators to 
retention; the majority were generalisable to clinical trials 
of people with newly diagnosed T1D. Coming to terms 
with a diagnosis of T1D, lack of time, work pressures, 
level of health professional support, volume, clarity and 
consistency of information and feedback and a desire 
for knowledge about their condition were all cited as 
influencing factors to trial retention.
Conclusions To our knowledge, this is the first qualitative 
study to examine the experience of being involved in 
an exercise trial by people with T1D. Findings suggest 
appointments could be shorter, available outside of 
working hours and planned longer in advance; study 
information should be clear, consistent and in electronic 
and paper formats; questionnaires need minimising; 
healthcare support and feedback needs providing 
regularly; thought is required around how to support 
non-exercising arm participants. These considerations 
may improve participant retention rates in new-onset T1D 
studies.
IntrODuCtIOn 
Type 1 diabetes (T1D) is a chronic autoim-
mune condition characterised by immune-me-
diated destruction of insulin-producing 
pancreatic β cells.1 Significant numbers of β 
cells are present at the time of diagnosis,2 and 
preservation of β cell function is associated 
with significant benefits for people with T1Ds. 
Interventions that can preserve residual β cell 
function in new-onset T1D are needed.
In animal models of T1D and type 2 diabetes 
(T2D), healthy humans and in people with 
impaired glucose tolerance withT2D, regular 
exercise has been shown to preserves β cell 
function.3 These findings have not been 
tested in people with T1D, and there is thus a 
need for a prospective clinical trial to test the 
hypothesis that exercise preserves β cell func-
tion in people newly diagnosed with T1D.
The Exercise for Type 1 Diabetes (EXTOD) 
study was a pilot study undertaken to explore 
whether exercise can preserve β cell func-
tion in adults newly diagnosed with T1D. In 
designing this study, we had to bear in mind 
that the incidence rate of T1D is low and 
recruitment of people with T1D to clinical 
trials is challenging.4–6 Other studies have 
shown recruitment rates as low as 17%.4 
This means that retaining people with newly 
diagnosed T1D who are recruited to studies 
is even more important. In studies of immu-
notherapeutic agents for T1D, dropout rates 
are 12%–14%7 8; however, higher rates have 
strengths and limitations of this study
 ► A qualitative, interview study was undertaken to 
explore, in-depth, the experiences of people with 
type 1 diabetes (T1D) who were participating in an 
exercise study.
 ► The study was multisite, taking place at five partici-
pating hospital trusts across the UK.
 ► Rigorous data collection and analysis techniques 
were undertaken, using the framework approach.
 ► Ethnicity excluded as a purposive sampling cri-
terion resulting in only white participants being 
represented.
 ► To our knowledge, this is the first qualitative study 
to examine people with T1D experiences of being 
involved in an exercise trial.
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been reported for exercise studies. In a meta-analysis of 
unsupervised exercise programmes for people with T2D, 
20% of studies had a dropout of >20%, 32% a dropout of 
10%–20% and 48% a dropout of <10%.9
Barriers to participation in clinical trials are well docu-
mented,10 although no studies have looked at barriers 
to recruitment in people with T1D. There are very few 
studies that have looked at how to improve retention rates 
of people with T1D in a clinical randomised controlled 
trial (RCT). Those studies that have been done have 
concentrated on strategies to improve retention rather 
than barriers to retention.11 No studies have looked at 
barriers to retention in people newly diagnosed with 
T1D. We wished to address this important deficit by qual-
itatively exploring the experiences of people with newly 
diagnosed T1D who participated in a recently completed 
exercise and T1D study.12 Here we report our findings 
from a qualitative study of barriers to clinical trial reten-
tion in adults with recently diagnosed T1D. We have not 
reported other findings from the EXTOD study, which 
are reported separately.13 14
MethODs
setting, access and recruitment
Study participants were from the EXTOD study, whose 
protocol has been described previously.12 In brief, all 
people aged between 16 and 60 years, diagnosed with 
T1D in the previous three months, from 19 UK hospital 
sites were invited to participate. The EXTOD study 
explored the barriers and benefits of exercise in adults 
with newly diagnosed T1D. The hypothesis being tested 
by the EXTOD study was that exercise preserved β cell 
function in adults recently diagnosed with T1D. EXTOD 
had two phases. Phase I consisted of a qualitative study 
to determine attitudes and barriers to exercise in people 
with newly diagnosed T1D.13 Phase II was a pilot RCT to 
assess uptake, intervention adherence, dropout rates and 
rate of uptake in the usual care group during a 12-month 
exercise intervention (where the participants came from 
for this study).
At the time of recruitment to the pilot RCT (phase II) 
study, all people with T1D received participant informa-
tion leaflets and provided informed consent to poten-
tially take part in an interview to explore their experience 
of being involved in the pilot RCT. Of the 60 participants 
who took part in the pilot RCT, 20 participants from 
five participating sites (Birmingham, Leeds, Bristol, 
Gloucester, Taunton) were later selected using purposive 
sampling to ensure variety and diversity in terms of their 
key study characteristics.15 Participants were sampled in 
relation to their age, gender, study arm (intervention/
control) and study status (completed/withdrawn) to 
ensure that an even spread of participants across the 
key characteristics were sampled. Similarly the sites were 
selected to allow a purposeful sampling of geographical 
areas participating in the EXTOD study (teaching hospi-
tals vs district general hospitals). Selected participants 
were sent a letter at the end of the pilot RCT, informing 
them that they would be contacted by the EXTOD team. 
This was followed, a week later, by a phone call from a 
member of the EXTOD team (nurse or doctor) to check 
they were happy to be interviewed. If willing, they were 
then telephoned by the researcher (CH), who has a 
nursing background and is an experienced qualitative 
researcher (though she had not previously undertaken 
any research in this area), to arrange a suitable time and 
date for her to undertake the interview. CH had had no 
contact with participants prior to this and participants 
were unaware of the researcher’s background. All partic-
ipants agreed to be interviewed.
Patient involvement
The research question was derived from people with T1D 
attending clinic and asking clinicians about any benefits 
and barriers to exercise as they were aware that much work 
had been undertaken on this topic in people with T2D, 
but not in people with T1D. This led to the formulation of 
the research question and an application for funding to 
undertake this research. People with T1D were involved 
in the study design from the outset as the researchers 
presented the study proposal to them and asked for any 
comments relating to it (approximately seven people with 
T1D were involved). Issues relating to the conduct of the 
study, such as the potential burden of the exercise inter-
vention to participants, were also discussed and any feed-
back was incorporated into the study design. People with 
T1D also contributed to the study conduct by sitting on 
the study management committee and helping with study 
oversight, including helping to develop approaches to 
improve study recruitment (three people with T1D were 
involved). Study findings for phase II of the study were 
fed back to participants through an informal feedback 
evening where the findings were presented. This was well 
received by the participants. In addition, a summary of 
findings was posted to participants.
Data collection
Participants at the hospital where the researcher was 
based (Birmingham) were given the option of being 
interviewed face-to-face at the hospital or by telephone. 
The remaining participants were all interviewed by tele-
phone due to financial, time and travel constraints. All 
interviews were carried out with only the participant and 
CH present.
Interviews were carried out by CH using a structured 
topic guide (table 1) that was developed in consul-
tation with the EXTOD researchers. The interviews 
lasted between 20 and 50 min. No repeat interviews 
were conducted. Areas for discussion included levels of 
health professional support, information provided about 
diet and exercise and issues relating to recruitment and 
follow-up. All interviews were digitally recorded and tran-
scribed verbatim by a local transcription company.
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Data analysis
Data analysis was carried out during the interview period 
to enable the interview process to be shaped by the 
emerging data themes and to identify when saturation 
had been reached. For example, some participants in 
the early interviews spoke of how they had struggled to 
Table 1 Topic guide for interview study
Openers If I could start by asking you how long ago you took part in the study? How did you find the experience?
Diet and exercise 
information
How appropriate was the advice about diet and exercise in relation to its content and volume?
Do you feel being recruited to the study so soon after diagnosis was a good thing or would you have 
preferred more time?
When would have been an appropriate time?
How well were able to take in the information you were given?
Would it have been helpful to see the dietician again, or do you feel that once was enough?
Did you refer to the study information booklet? If so, how helpful was the information booklet?
Which sections of the booklet particularly helpful or unhelpful?
Do you use the booklet as a reference guide now?
Did any aspects of your diet change following looking at the information booklet?
Can you think of any better ways in which the information could have been delivered?
Health 
professional 
support
How well supported did you feel in terms of the clinical support you received?
Did you feel you more or less well supported through being on the trial?
Do you feel being in the trial was better or worse in terms of the number of doctors/nurses you saw? Why?
Were you happy seeing the same nurse all the way through the trial or would you have preferred more 
variety? Did you mind no longer seeing the nurse you saw when you were diagnosed?
Do you mind not seeing these study doctors/nurses on a regular basis now?
How well balanced were the follow-up visits in terms of the health professional you saw? Would you have 
preferred more/less visits with a doctor/nurse etc… Or do you feel it was the right amount of time with 
each?
Overall, how well supported by the doctors and nurses did you feel?
Recruitment and 
follow-up
Where did you first hear about the trial from? Who approached you?
What appealed to you about taking part in the study in the first place? What were your reasons?
Was there anything that put you off taking part in the study?
How easy to complete and understand were the questionnaires you received?
During the trial you were required to have extra blood tests. How did you feel about having the extra 
bloods?
How much did you feel the follow-up visits were focused on you and how much did you feel they were 
focused on the trial and form filling etc… Was this appropriate or could it be weighted differently?
Would you have preferred most of the follow-up visits to have taken place face to face or over the phone?
Can you describe whether being on the study affected your confidence levels in terms of undertaking 
exercise?
What were your reasons for leaving the study?
Why did you choose to continue/discontinue with the 5-year follow-up as part of the study?
Motivational 
interviewing 
(intervention 
group only)
How useful do you feel the extra support you were given by the nurse about managing your diabetes and 
exercising was? What were the pros and cons of talking to the nurse about this?
Would it have been helpful to have weekly phone calls from the nurse to check on how you were getting on?
Did the amount of exercise you undertook change as a result of these talks with the nurse or did it stay the 
same?
Did the type of exercise you undertook change or stay the same following (a) diagnosis and (b) the 
intervention?
How much physical activity were you carrying out before your diagnosis compared with (a) during the study 
and (b) now? Has your exercise levels been maintained post-study?
Did you feel more or less confident about carrying out exercise following the intervention with the nurse?
What more could have been done to encourage you to exercise?
What sort of approach might have worked for you to help you to exercise?
Some participants did not make their exercise target. Can you think how we could help them reach this 
target?
What methods did you use to increase your exercise levels?
Future 
development of 
study
If there was one thing we could do to make the study easier for you to take part in what would it be?
We are planning to undertake a larger scale study similar to the one you have taken part in. What sort of 
things would you change about the study that might make people want to take part in it more?
Overall, what did you feel was good or bad about taking part in the study?
Do you think you would be more or less likely to participate in clinical trials following this experience?
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come to terms with their new T1D diagnosis. As a result, 
subsequent interviews explored this area in more depth, 
focusing on the impact this had on their experience of 
participating in the EXTOD study. An inductive approach 
to data analysis was taken and themes were derived from 
the interview dataset. The predetermined topic areas set 
out in the topic guide (table 1) such as ‘health profes-
sional support’ and ‘recruitment and follow-up’ guided 
the analysis process as much of the data collected focused 
on these topic areas, enabling the researchers to elicit 
information that was relevant to the study question. 
Data were coded by CH and were inserted into a frame-
work analysis matrix Excel spreadsheet, to enable data 
ordering and synthesis, while retaining the meaning and 
feeling of the interviewees’ words.16 Themes were devel-
oped by CH by reading and rereading the transcripts and 
these themes were then agreed during discussions with 
research team members (CH, PN and SG). The inter-
views were then analysed using thematic analysis.17 Tran-
scripts were not returned to participants to comment on 
during this process.
results
Participants
In total, 20 participants were interviewed; 6 face-to-face 
and 14 by telephone (table 2). Participants were recruited 
from all five participating sites; 11 were men, ages ranged 
from 19 to 55 years and all were of white British ethnic 
origin. Thirteen had been allocated to the intervention 
group and seven to the usual care comparator. Sixteen 
participants had completed EXTOD, while four had 
withdrawn for reasons including work commitments, a 
cancer diagnosis and difficulties accepting their diabetes 
diagnosis.
themes
The interviews yielded data on five main themes, and 
these help formulate the barriers and facilitators to trial 
participation (Box 1). These themes were study paper-
work, feedback, barriers to continued participation, 
coming to terms with diagnosis of T1D and effect of allo-
cated arm.
Study paperwork
Two main subthemes emerged within the ‘study paper-
work’ theme; these were study information and study 
questionnaires.
Study information
The volume, clarity and consistency of information 
provided were important in determining how well 
informed participants felt about their diabetes and its 
management. Though a few participants felt they were 
given too much information, most felt that although there 
was a lot of information, it was useful, relevant and neces-
sary so soon after diagnosis. Generally the information 
was cited as interesting, manageable and straightforward. 
Table 2 Characteristics of participants
Participant Gender Centre Treatment arm Complete/with drew Interview format
1 Female Birmingham Intervention Completed Telephone
2 Male Birmingham Control Completed Face-to-face
3 Male Birmingham Intervention Completed Face-to-face
4 Female Birmingham Intervention Withdrew Telephone
5 Male Leeds Intervention Withdrew Telephone
6 Female Leeds Control Withdrew Telephone
7 Female Birmingham Intervention Completed Face-to-face
8 Female Birmingham Intervention Completed Face-to-face
9 Male Birmingham Control Completed Face-to-face
10 Male Birmingham Control Completed Telephone
11 Male Birmingham Intervention Completed Telephone
12 Male Taunton Intervention Completed Telephone
13 Male Gloucester Control Completed Telephone
14 Female Bristol Intervention Completed Telephone
15 Male Bristol Control Completed Telephone
16 Male Bristol Intervention Completed Telephone
17 Male Bristol Control Withdrew Telephone
18 Female Leeds Intervention Completed Telephone
19 Female Birmingham Intervention Completed Face-to-face
20 Female Taunton Intervention Completed Telephone
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Others spoke of how they valued the repetition of some 
information as it meant they could fully absorb it.
To be honest I thought it was perfect … I was sort of 
drip-fed information throughout the year really, and 
it was very good … After … The shock of being told 
you’re Type 1 diabetic … I found it very good and 
the team was extremely helpful. EXTOD 12 (male, 
Taunton)
Most participants were happy receiving paper infor-
mation, finding it easy to read and acknowledging that 
not everyone had internet access. Others, especially 
younger participants, stated they would have preferred 
digital information, such as apps, to access information 
faster. One participant suggested having a centralised 
webpage specific to the hospital’s diabetes unit, with 
links to different diabetes resources on it. Participants 
supplemented the trial information with other resources, 
such as the ‘Carbs and Cal’ book.18 Others used digital 
resources, such as the ‘Carbs and Cal’ or ‘Fitness Pal’ apps 
and online information.18
Being a bit of a technology geek, I went with the app 
which is the Carbs and Cals app … It will give you 
a particular breakfast, like Alpen … and then it will 
show you … the size of portion that you’re supposed 
to have, and how much insulin you’re supposed to 
take. EXTOD 2 (male, Birmingham)
Study questionnaires
Most participants felt the study paperwork was too long 
and time-consuming, ‘switching off’ from it as a result, 
as it got in the way of work and personal lives. Much 
paperwork was questionnaires relating to diet, exercise 
and quality of life that were completed at the study visit. 
Participants felt that although the paperwork was gener-
ally easy to complete and understand, it could also be 
repetitive, confusing and contradictory, containing irrel-
evant, non-specific questions, which were hard to relate 
and respond to.
I remember always getting given the questionnaire 
sheet when I was having my bloods done. And I could 
just never fill it in. It used to be like – I used to say to 
my dad can you ask my questions and then I could do 
it, but it did go on for quite a while …  And it was the 
same the second time I did it as well, and I was like 
I don’t know what to put for these questions again. 
It seemed like I was doing the same thing. EXTOD 
19 (female, Birmingham)
Feedback
Some participants voiced disappointment at receiving 
little trial feedback, stating that the opportunity for feed-
back had incentivised them to join the trial, as a way of 
finding out about their diabetes and also that they wanted 
to learn more about the long-term trial outcomes.
It would be good to have some follow-up information 
… I wasn’t quite sure how my fitness level was affected 
… And I never got to find out if it actually improved. 
EXTOD 1 (female, Birmingham)
Barriers to continued participation
In total, 17 of the 58 participants who were randomised 
into the original EXTOD study withdrew before the end 
of the study. We thus sought to understand why this might 
have happened.
Participants described practical barriers as the most 
likely reasons for dropping out. These included time 
and work pressures, dislike of blood tests, travelling to 
appointments, the long study duration, volume of visits 
and moving away.
I’m not bothered for taking blood or doing injections 
or anything like that … But I can remember feeling 
bothered by that at the time. I think because I was 
very ill, really, still, and still quite fragile … I can re-
member that upsetting me … Because it was a study 
and because I didn’t have to do it … If you volun-
teered to have a blood test and it takes a few times 
for them to take the blood, it’s kind of like putting 
yourself through something difficult that you didn’t 
really need to do. EXTOD 6 (female, Leeds)
The long study duration also deterred many partici-
pants, who felt it was too long to fully commit to, meaning 
they became less vigilant at attending appointments or 
completing study documentation due to the repetition 
involved.
It’s quite long. I think that was quite daunting. It 
turned out to not really be an issue, but because it’s 
something that I could kind of blend into my lifestyle 
box 1 Facilitators and barriers to continued clinical trial 
participation in people with type 1 diabetes mellitus
Facilitators
 ► Consistency and continuity of health professional support
 ► Clear, detailed and relevant information about diabetes and its 
management
 ► Availability of both paper and electronic information and 
documentation
 ► Reduction in volume of study documentation
 ► Flexible access to trial facilities outside of normal working hours
 ► Appointments scheduled in advance to allow for planning around 
work and social lives
 ► Early feedback of trial findings
barriers
 ► Time
 ► Work pressure
 ► Travelling to appointment
 ► Length of visits
 ► Length of study
 ► Coming to terms with diagnosis
 ► Being able to maintaining exercise levels
 ► Being allocated to the control (non exercising arm)
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quite a lot. Because I suppose it didn’t really require 
any prolonged visits to the clinic or anything because 
it was mostly just things that I could do myself. But 
initially that was a bit daunting because it’s a year. 
EXTOD 16 (male, Bristol)
For most, committing to the EXTOD study had proved 
difficult, due to the time it required off work. This let to 
difficulties for participants in ensuring they could always 
attend appointments and sometimes proved costly due to 
having to take unpaid leave for study visits.
The time that you’re having to have off work … Often 
it’s unpaid leave so obviously that can be quite diffi-
cult. EXTOD 18 (female, Leeds)
These time pressures had led to two of the interviewed 
participants withdrawing from EXTOD prior to comple-
tion. Solutions to these problems suggested by partici-
pants—who had both withdrawn and remained in the 
study—included offering more flexible appointment 
times and planning clinic visits further in advance so 
there was more time to plan around them.
I left … Because I didn’t have enough time … The 
study is of such a long duration and I just found that 
too challenging with work … If you had appoint-
ments at eight o’clock in the evening every time you 
needed me then so be it … I have to do a hell of a lot 
of juggling in order to fit that sort of stuff in. EXTOD 
17 (male, Bristol)
Coming to terms with diagnosis of T1D
Some participants spoke of how they had struggled to 
come to terms with their T1D diagnosis, with one partic-
ipant citing this as their reason for withdrawing from 
EXTOD. For this participant, her difficulties coping 
emotionally with her diagnosis had prompted her doctors 
to advise her to withdraw.
Don’t think it kind of really sank in as to what I’d 
been diagnosed with … It had kind of hit me and I 
wasn’t really dealing with having it … I wasn’t taking 
my insulin and checking my levels as much … The 
doctors … Felt that it was best that I was taken off it. 
EXTOD 4 (female, Birmingham)
Effect of allocated arm
Some participants, who had been allocated the exercise 
intervention, spoke of difficulties maintaining the level 
of exercise expected of them due to lack of motivation or 
the extra time it took.
I think a year in it seemed to get a little bit ‘Oh God 
I’ve been doing this for a year now’ … A year’s a long 
time … Because towards the end as well, it was like 
you had to come in and then I had to do the gym 
thing, and it was kind of like … ‘oh this is getting re-
ally laborious’. EXTOD 2 (male, Birmingham)
Others, in the usual care comparator group, spoke of 
how this disincentivised them from remaining in EXTOD 
as they were not receiving the exercise benefits they had 
hoped for.
The sort of people that … Take part … Are often sim-
ilar to me in kind of quite wanting to do the exer-
cise, and presumably about half of the time you get 
randomised into not doing the exercise. And I don’t 
know whether that’s off-putting as well. EXTOD 
16 (male, Bristol)
DIsCussIOn
This is the first study to examine the experiences of 
people with T1D taking part in an exercise intervention 
trial. The findings have highlighted issues that should 
be considered when designing clinical trials involving 
this population group. Clinical trials which reflect the 
needs, wants and preferences of participants can lead to 
improvements in retention rates, statistical power and, in 
the longer term, to studies with more credible findings. 
The findings suggest that timing is an important consid-
eration for many participants. Many may be offered trial 
entry shortly after their condition’s onset and may be 
experiencing multiple health and lifestyle changes and 
struggling to come to terms with their diagnosis of T1D. 
This highlights the need for sensitive communication of 
information from health professionals when introducing 
clinical trials to adults with T1D as they may be experi-
encing tensions between not wanting to ‘become’ their 
new illness or allow it to govern them, while reconciling 
that they need to be adaptable to their illness if they are 
going to feel well again.19 20 The disappointment of some 
participants at being allocated the usual care group also 
highlights the need for a clear explanation of equipoise 
and other clinical trials terminology, so participants can 
make informed treatment decisions, minimising the 
potential for withdrawal rates after randomisation.21 
Additional measures that could help with this are offering 
the intervention at the end of the study or randomising 
more to the exercise arm than the control arm, to enable 
more participants access to the intervention.
The study has illustrated the need for the transmis-
sion of clear, relevant and useful information to clinical 
trial participants. Participants showed preferences for a 
wide range of delivery modes, including paper formats, 
websites, apps and internet forums. The use of appro-
priate, accessible media to convey information effectively 
and engage with participants is dependent on individual 
preferences and may be influenced by factors such as 
age, gender and income.22 The popularity of apps and 
multimedia technologies among participants indicates 
that these modes of information delivery should be incor-
porated specifically into trials with T1D participants, who 
are likely to be a younger, more technologically minded 
population group than trials with T2D participants. 
Future trial designs could offer paper and electronic 
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information so participants can use their preferred 
resource. Similarly, when collecting data, a range of 
methods could be employed, including paper documen-
tation, spreadsheets, phone apps, emails and websites. 
Demonstrating versatility and flexibility in data collection 
techniques may help motivate participants to complete 
study documentation that they might otherwise omit. The 
importance of providing regular study feedback to partic-
ipants should also be considered, through letters, emails 
and presentations, so that their contribution is acknowl-
edged and valued.23
Finally, the interview findings highlighted that practi-
calities such as work pressures, time commitments and 
geographical location influenced participants’ ability to 
commit to the trial. T1D onset usually occurs at a young 
age, with most people being diagnosed before 35.24 As a 
result, people with T1D are likely to have busy lives incor-
porating work, family and social engagements, making 
committing to a clinical trial difficult. This is verified 
by the most common reason cited for the high dropout 
rate (29%) from EXTOD being time and work commit-
ments. To rectify this, more flexible study visit times could 
be offered, with the option of attending outside normal 
working hours, such as evenings and weekends. Addition-
ally, the provision of a timetable of scheduled appoint-
ments at the study outset would allow participants to plan 
for them. Improved hospital transport links could also 
facilitate ease of study attendance.25 By incorporating a 
flexible approach to these practical barriers, participants 
will experience less difficulty in complying with study 
visits, improving retention rates. Consideration should 
also ensure that the exercise intervention can be inte-
grated into people’s lifestyles, without adding to their 
pressurised schedules. This could be done by providing 
a range of exercise options, in a range of locations and 
within a realistic time frame, to minimise the likelihood 
of participants becoming overfaced by the extra commit-
ment they have taken on.
Many of the challenges to clinical trial retention in 
people with T1D are similar to the challenges facing the 
general population who are recruited to clinical trials.26–30 
The issues and challenges participants faced, such as the 
long study duration, difficulties completing documenta-
tion and time pressures, are also likely to be challenges 
for the general clinical trials population, including T2D. 
However, this study has identified that although many of 
these trial-related issues are not specific to T1D popula-
tions, the reasons for these issues are likely to be different. 
For example, people with T1D or T2D may report that 
time pressures prevent them from committing to a clinical 
trial. However, while for the T1D participant time pressures 
may stem from work priorities, the T2D participant time 
pressures may stem from regularly caring for grandchil-
dren. By understanding more about the reasons behind 
these barriers to trial recruitment and retention, trials 
can be designed to accommodate and facilitate the wants 
and needs of these different groups. The average age of 
participants entering clinical trials is >50 years of age.28–31 
While there is growing evidence that T1D is diagnosed 
throughout adult life,32 33 the mean age of the randomised 
EXTOD participants was 32 years, suggesting that trial 
retention considerations should focus on needs of younger 
adult populations. This younger age group is likely to face 
more difficulties in adhering to rigid time schedules and 
appointments due to added work, family and social pres-
sures. This is important for clinicians and researchers to 
acknowledge, allowing them to design T1D studies that will 
facilitate trial recruitment and retention, by offering more 
flexible appointment times, out-of-hours services and 
realistic, manageable exercise schedules. These practical 
solutions are important considerations for retaining partic-
ipants in clinical trials and must be valued if rich and full 
trial datasets are to be obtained. These considerations may 
also have some relevance for T2D populations, with the 
average age of onset for this disease getting younger.33 34 
When considering study design, thought must be given 
to how to increase recruitment, as well as how to make 
the study experience appealing to participants once they 
have consented. By paying attention to the participant’s 
perspective, the chances of retaining participants for the 
study duration will increase, improving trial outcomes and 
participant satisfaction with trial entry.
strengths and limitations
The interview participants were selected from five UK 
hospitals, increasing the transferability of the findings to 
a range of settings. Participants were purposively sampled, 
stratifying them according to age, gender, randomisa-
tion arm and whether they had completed or withdrawn 
from the study. This enabled a diverse and comprehen-
sive collection of narratives to be gathered and analysed, 
enhancing the trustworthiness of the findings. However, 
although 12% of EXTOD participants recruited were 
non-white, none of the participants recruited to the qual-
itative study were non-white. This lack of representation 
is due to our exclusion of ethnicity as a criterion in our 
purposive sampling. Although we did not purposefully 
exclude non-white participants from the sample, the 
likely reason for their lack of inclusion is because T1D is 
far more common in white populations than other ethnic 
groups.35 Additionally, many of the geographical locations 
we recruited from had a white population of >84%.36–38 
Despite this, including ethnicity in our purposeful sample 
could have ensured that non-white populations were 
represented. In addition, due to the interview partici-
pants being situated around the UK, most interviews were 
conducted by telephone. However, where possible, partic-
ipants were given the choice of being interviewed face-to-
face or by telephone, allowing them to choose the setting 
they found most relaxing, thus increasing opportunity 
for open dialogue between interviewees and researchers. 
The fairly even split between participants choosing face-
to-face and telephone interviews suggests that providing a 
choice of setting may increase recruitment and retention 
to trials, giving participants the opportunity to select their 
most comfortable environment.
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COnClusIOn
To our knowledge, this is the first qualitative study to 
examine T1D participants’ experiences of being involved 
in a clinical trial. Although people may be initially moti-
vated to enter clinical trials for reasons such as altruism 
and a desire for information, practical factors such as 
work and time constraints, study duration and financial 
difficulties often act as deterrents for remaining on trials. 
Though these issues in themselves are not unique to the 
T1D population, the reasons for these issues are likely 
to be different. These reasons need considering when 
designing T1D clinical trials, to ensure that appropriate 
modifications are built into the trial design to enable 
people with T1D to participate with minimal disruption 
to their lives.
The study findings have highlighted that differences do 
exist between T1D participants and the general clinical 
trials population. First, despite T1D increasingly being 
diagnosed in adult life, the younger adult age of people 
with T1D at recruitment may make it harder for them to 
commit to clinical trials due to increased work, family and 
social pressures; this was verified by study participants. 
Second, the study has indicated that using multimedia 
technology might benefit T1D participants, who are used 
to handling information electronically. It has highlighted 
that to increase retention to T1D trials improvements 
to trial design are required. This can be done through 
providing flexible access to services, clear and relevant 
study information, documentation and feedback, as well 
as consistent healthcare support.
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